Test your knowledge of relapsed multiple myeloma and bispecific antibodies

Teclistamab is a bispecific antibody directed against CD3 and which of the following?
GPRC5D
SLAM7
BCMA
CD38
Teclistamab is a good option for someone relapsing after two lines of therapy.
True
False
The median onset of cytokine release syndrome (CRS) is how long after treatment initiation?
7 days
2 days
1 day
14 days
{"name":"Test your knowledge of relapsed multiple myeloma and bispecific antibodies", "url":"https://www.poll-maker.com/QBK0KO5PY","txt":"Teclistamab is a bispecific antibody directed against CD3 and which of the following?, Teclistamab is a good option for someone relapsing after two lines of therapy., The median onset of cytokine release syndrome (CRS) is how long after treatment initiation?","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}